{"entity":{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","aka":[],"tldr":"Dutch national cancer centre that pioneered neoadjuvant immunotherapy (NADINA, NICHE) and TIL therapy in Europe.","summary":"The Netherlands Cancer Institute, NKI-AvL in Amsterdam, is the Dutch national cancer centre, ranked forty-fifth in the Newsweek/Statista oncology list, and the place where neoadjuvant immunotherapy and TIL therapy were pioneered in Europe. Its NADINA trial in melanoma and NICHE-2 trial in mismatch-repair-deficient colon cancer changed practice, John Haanen's randomised trial of TIL therapy against ipilimumab was the first of its kind, and MammaPrint originated here with van 't Veer; Christian Blank, Myriam Chalabi, René Bernards and Emile Voest are also listed. OnCo links it to OVHIPEC-1, to the DRUP model for off-label targeted drugs in rare tumours, and to HOVON and the KWF Dutch Cancer Society. Getting academic cell therapies to patients at scale is the bottleneck it now faces. Its neoadjuvant, TIL and breast genomics programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nki.nl"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy","checkpoint-inhibitor","mr-linac"],"targets":[],"drugs":["tacquell"],"companies":[],"institutions":[],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":[],"people":["rene-bernards","sabine-linn","willemien-van-driel","winette-van-der-graaf","paul-baas","christian-blank","emile-voest","john-haanen","myriam-chalabi","ton-schumacher","maurice-van-den-bosch","rene-medema"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.348,"lng":4.855,"institutionType":"cancer-center","website":"https://www.nki.nl","newsweekOncology2026":45,"programs":["Neoadjuvant immunotherapy","TIL therapy","Breast genomics"]},"route":"/institutions/nki/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"tacquell","kind":"drug","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/"}],"term":[{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"}],"person":[{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/"},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/"},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/"},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/"},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/"},{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/"},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/"},{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/"},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/"},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/"},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/"},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"trial":[{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/"},{"id":"netherlands-hipec","kind":"trial","name":"Netherlands Cancer Institute HIPEC trial","route":"/trials/netherlands-hipec/"},{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/"},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/"}],"paper":[{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/"},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"},{"id":"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003","kind":"paper","name":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","route":"/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/"},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"}],"bottleneck":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"idea":[{"id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/"},{"id":"idea-bio1-mechanism-matched-access","kind":"idea","name":"A fast route to the matched drug when it is licensed for another cancer","route":"/ideas/idea-bio1-mechanism-matched-access/"},{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/"},{"id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/"},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/"},{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","route":"/ideas/idea-fund-payer-funded-pragmatic-trials/"},{"id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/"},{"id":"idea-fund-surgical-outcomes-public-reporting","kind":"idea","name":"Public risk-adjusted outcome reporting for cancer surgery to drive centralisation","route":"/ideas/idea-fund-surgical-outcomes-public-reporting/"},{"id":"idea-tr1-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the cancer registry: registry-based trials for everyday questions","route":"/ideas/idea-tr1-registry-embedded-randomisation/"},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/"}],"pathway":[{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/"}],"institution":[{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","route":"/institutions/amsterdam-umc/"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/"},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/"},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/"}],"company":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/"}]}}